H.C. Wainwright analyst Edward White maintained a Buy rating on Chemocentryx Inc. on Tuesday, setting a price target of $83, which is approximately 75.66% above the present share price of $47.25.
White expects Chemocentryx Inc. to post earnings per share (EPS) of $0.32 for the fourth quarter of 2020.
The current consensus among 7 TipRanks analysts is for a Strong Buy rating of shares in ChemoCentryx (NASDAQ:CCXI), with an average price target of $73.83.
The analysts price targets range from a high of $84 to a low of $60.
In its latest earnings report, released on 06/30/2020, the company reported a quarterly revenue of $49.28 million and a net profit of $20.39 million. The company's market cap is $3.26 billion.
According to TipRanks.com, H.C. Wainwright analyst Edward White is currently ranked with 5 stars on a 0-5 stars ranking scale, with an average return of 22.5% and a 44.96% success rate.
ChemoCentryx, Inc. is a biopharmaceutical company engages in the development and commercialization of medicines. It focuses on inflammatory disorders, autoimmune diseases, and cancer. Its drug candidates such as Avacopan and CCX140, selectively blocks a specific chemoattractant receptor, leaving the rest of the immune system intact. The company was founded by Thomas J. Schall in 1997 and is headquartered in Mountain View, CA.